Search results for "Storage disorder"

showing 8 items of 18 documents

39 Formation of a Lysosomal Disease Testing Network to enhance the delivery of diagnostic services to patients with lysosomal storage disorders

2007

Endocrinologybusiness.industryEndocrinology Diabetes and MetabolismGeneticsMedicineSubstrate reduction therapyLysosomal storage disordersDiseaseBioinformaticsbusinessMolecular BiologyBiochemistryMolecular Genetics and Metabolism
researchProduct

Hornhaut-Schlüsselbefunde im Kindesalter als Hinweis für therapierbare systemische Stoffwechselerkrankungen

2013

Es gibt eine Reihe von systemischen lysosomalen Stoffwechselerkrankungen, bei denen bereits im Kindesalter krankheitsspezifische Hornhauttrubungen zu beobachten sind. Unter Lysosomen verstehen wir winzige Zellorganellen, die vom Golgi-Apparat gebildet werden. Sie enthalten verschiedene hydrolytische Enzyme und Phosphatasen, womit Fremdstoffe oder korpereigene Stoffe verdaut werden konnen. Die richtige Einordnung der Hornhautveranderung durch den Augenarzt an der Spaltlampe kann zur richtigen Diagnose der jeweiligen systemischen Stoffwechselerkrankung fuhren. Eine moglichst fruhe Diagnosestellung ist aktuell besonders bedeutend, da heute einem Grosteil der Patienten mit einer Speicherkrankhe…

GynecologyOphthalmologymedicine.medical_specialtybusiness.industrymedicineLysosomal storage disordersCornea verticillatamedicine.symptombusinessKlinische Monatsblätter für Augenheilkunde
researchProduct

Treatment of Lysosomal Storage Disorders (LSDs)

2020

Lysosomal Storage DiseasesPharmacologybusiness.industryDrug DiscoveryHumansMedicineLysosomal storage disordersLysosomesBioinformaticsbusinessCurrent Pharmaceutical Design
researchProduct

Lysosomal storage disorder in non-immunological hydrops fetalis (NIHF) - more common than assumed? Report of four cases with transient NIHF and a rev…

2012

Abstract Background Lysosomal storage disorders (LSD) are a rare cause of non immunological hydrops fetalis (NIHF) and congenital ascites. The reported incidence is about 1%. The incidence of idiopathic NIHF is estimated to be about 18%. Patients and methods We report four cases with transient hydrops fetalis resulting from LSD and performed a literature review on LSD with NIHF and congenital ascites in combination. Results At present, 12 different LSDs are described to be associated with NIHF or congenital ascites. Most patients had a family history of NIHF, where the preceding sibling had not been examined. A diagnostic approach to the fetus with NIHF due to suspected LSD either in utero …

MalePathologymedicine.medical_specialtyHydrops FetalisNon-immunological hydrops fetalisPharmacology toxicologylcsh:MedicineLysosomal storage diseaseLysosomal storage disordersClinical approachPregnancyHydrops fetalisAscitesLysosomal storage diseaseHumansMedicineGenetics(clinical)Pharmacology (medical)Genetics (clinical)Medicine(all)business.industryResearchIncidence (epidemiology)lcsh:RTransient hydropsGeneral Medicinemedicine.diseaseCongenital ascitesLysosomal Storage DiseasesImmunologyFemalemedicine.symptombusinessOrphanet Journal of Rare Diseases
researchProduct

743 Lysosomal Storage Disorders in Non-Immunological Hydrops Fetalis - More Common than Assumed?

2012

Background Although non immunological hydrops fetalis (NIHF) is a very rare disorder, the disturbance accounts for a disproportionate share (3%) of overall mortality in the perinatal period. Lysosomal storage disorders (LSD) are only exceptionally considered to be the cause of NIHF. The reported incidence is about 1%. On the other hand, in about 18% of all cases, NIHF is classified as idiopathic. Patients and methods We report four cases of transient NIHF due to LSD and reviewed the literature for LSD associated with NIHF. Results At present, 12 different LSD are described to be associated with NIHF. The majority of reported patients already had a family history of NIHF, which had not been …

Pathologymedicine.medical_specialtyFetusPediatricsbusiness.industryGenetic counselingIncidence (epidemiology)Lysosomal storage disordersEnzyme replacement therapymedicine.diseaseHydrops fetalisPediatrics Perinatology and Child HealthEtiologyMedicineFamily historybusinessArchives of Disease in Childhood
researchProduct

Clinical guidelines for diagnosing and managing ocular manifestations in children with mucopolysaccharidosis.

2011

The mucopolysaccharidoses (MPS) are a group of rare lysosomal storage disorders characterized by the accumulation of glycosaminoglycans in several tissues and organs. This accumulation results in an array of clinical manifestations and premature death in severe cases. Ocular problems are very common in children with MPS and may involve the cornea, sclera, trabecular meshwork, retina, optic nerve and also the posterior visual pathways. The aims of this study are to give an overview of ocular problems in MPS and to provide clinical guidelines for paediatric ophthalmologists for early diagnosis and management of ocular manifestations in children with MPS. Diagnostic problems may arise in child…

Pediatricsmedicine.medical_specialtygenetic structuresEye DiseasesMucopolysaccharidosisLysosomal storage disordersDiagnostic Techniques Ophthalmological03 medical and health sciences0302 clinical medicineOphthalmologyCorneaPrescription glassesMedicineHumansChildbusiness.industryInfant Newbornnutritional and metabolic diseasesInfantGeneral MedicineMucopolysaccharidosesmedicine.diseaseeye diseases3. Good healthScleraOphthalmologyPremature deathmedicine.anatomical_structureEyeglassesChild PreschoolPractice Guidelines as Topic030221 ophthalmology & optometryOptic nerveQuality of Lifesense organsTrabecular meshworkbusiness030217 neurology & neurosurgeryActa ophthalmologica
researchProduct

Enzyme replacement and gene therapy for mucopolysaccharidoses: current progress and future directions

2015

Introduction: Mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by the deficiency of enzymes that are responsible for the stepwise degradation of complex carbohydrates, the glycosaminoglycans. Whereas in the past the treatment of MPS consisted mainly of palliative care, enzyme replacement therapy (ERT) is now possible for some MPS disorders, and in the future many other therapeutic options will become available.Areas covered: This review, based on personal experience and the currently available literature, will give an overview on the efficacy and limitations of ERT and will discuss new therapeutic approaches, such as anti-inflammatory drugs, substrate reduction therapy, ch…

congenital hereditary and neonatal diseases and abnormalitiesPalliative carebusiness.industryHealth PolicyGenetic enhancementmedicine.medical_treatmentnutritional and metabolic diseasesLysosomal storage disordersHematopoietic stem cell transplantationEnzyme replacement therapyBioinformaticsImmunologymedicinePharmacology (medical)Substrate reduction therapybusinessPharmacology Toxicology and Pharmaceutics (miscellaneous)Expert Opinion on Orphan Drugs
researchProduct

Comment: Why are females with Fabry disease affected?

2019

medicine.medical_specialtyHunter Syndromebusiness.industryHunter syndromemedicine.diseaseLysosomal Storage DisorderFabry diseaseEndocrinologyEndocrinologyInternal medicineGeneticsmedicineFabry DiseaseX-inactivationX-linked DisorderbusinessMolecular BiologyLetter to the Editor
researchProduct